- $11.87m
- -$11.39m
- $1.98m
Brief: Lipocine Announces Continued Commercialization Of Tlando
U.S. STOCKS ON THE MOVE-ONEOK, US hospital operators, BridgeBio
Lipocine rises on licensing deal for testosterone therapy in US, Canada
Brief: Lipocine And Verity Pharma Enter Into License Agreement For Tlando Franchise In US And Canada
Brief: Lipocine Inc Files For Mixed Shelf Of Upto $150 Million
Lipocine Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Lipocine To Present Clinical Data On Lpcn 1148 At The Liver Meeting® 2023
Brief: Lipocine Completes Successful Meeting With FDA On Lpcn 1154 In Postpartum Depression
Brief: Lipocine Inc - On Oct. 2, 2023, Co Received Notice From Antares Of Antares' Termination Of License Agreement
Lipocine Inc reports results for the quarter ended in June - Earnings Summary
Lipocine Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: LPCN 1148 Phase 2 Study Meets Primary Endpoint In Patients With Cirrhosis
Brief: Lipocine Regains Compliance With Minimum Bid Price Requirement
Brief: Positive Topline Clinical Results Support Streamlined Development Pathway For LPCN 1154
Lipocine falls on approval of reverse stock split, wider Q1 loss
Brief: Lipocine Inc says On May 10 Board Of Directors Approved A Reverse Stock Split Ratio Of 1-For-17
Lipocine Inc reports results for the quarter ended in March - Earnings Summary
Brief: Lipocine Announces Financial Results For Q1 Ended March 31, 2023
Lipocine Inc expected to post a loss of 2 cents a share - Earnings Preview